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Studies in patients with Bartter’s and Gitelman’s syndromes
performed in the last 10 years have provided important
insights into the mechanistic details of relevant pathways of
angiotensin II signaling and vascular tone regulation,
therefore making these syndromes a good human model to
gain insight into the mechanisms responsible for
maintaining/controlling vascular tone. Extensive studies of
patients with Bartter’s/Gitelman’s syndromes have, in fact,
shown biochemical abnormalities of angiotensin II short- and
long-term cell signaling, which depict a mirror image of those
found in hypertension. The information obtained from the
study of this human model of altered vascular tone
regulation show that it can be used to gather more general
data and/or confirm mechanistic details of the cellular and
biochemical events involved in the pathophysiology of
vascular tone control and to shed light on the multiplicity of
the angiotensin II signaling-related mechanisms responsible
for the pathophysiology of hypertension and its long-term
complication such as cardiovascular remodeling and
atherogenesis.
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THE ANGIOTENSIN II SIGNALING
Angiotensin II (Ang II) is one of the most important
humoral factors involved in the vascular alterations in
hypertension.1 The multiple actions of Ang II are mediated
via specific, complex intracellular signaling pathways that are
activated after binding of the peptide to its cell-surface
receptors. Although the elucidation of Ang II-mediated
signaling has made considerable progress in the last years, the
complete enumeration and understanding of the biochemical
processes that mediate Ang II abnormal cell signaling in
hypertension in humans still remains to be finished. Our
current understanding of Ang II demonstrates that pleio-
tropic cellular effects of Ang II are, in fact, mediated by the
activation of a multiplicity of signaling mechanisms.1,2 These
include monomeric and heterotrimeric G proteins, phospho-
lipase Cb, release of intracellular messengers such as inositol
trisphosphate and Ca2þ , and activation of protein kinase C,
leading to the well-characterized hemodynamic and endo-
crine effects of Ang II including vascular smooth muscle
contraction.3,4 These signaling pathways are counterbalanced
by the vasodilatory and antiproliferative activity of nitric
oxide (NO) system.5,6 Therefore, the multiple inter-relation-
ships that link hypertension, Ang II, oxidative stress, and NO
systems suggest that Ang II, oxidative stress, and NO
comprise a homeostatic system that regulates both vascular
function and structure.2 However, the involvement of and the
functioning of these systems have been demonstrated
primarily as a result of studies carried out either ‘in vitro’
or through the use of animal models. The results of these
studies therefore must be extrapolated to humans2 and need
to be confirmed by data both in vivo or ex vivo from humans.
INSIGHTS FROM STUDIES IN BARTTER’S/GITELMAN’S
SYNDROMES
In response to this need, we have proposed that Bartter’s/
Gitelman’s syndromes could be very useful for the evaluation,
confirmation, and understanding of the mechanisms being
identified as involved in Ang II signaling in humans.
Specifically, this mini review is designed to detail how the
study of this human model of altered vascular tone regulation
has been and can be used not only to confirm mechanistic
details of the cellular and biochemical events involved in
the pathophysiology of vascular tone control but also to
provide additional insight as to other potential Ang II
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signaling-related mechanisms that contribute to the patho-
physiology of hypertension.7,8
The clinical picture of Bartter’s and Gitelman’s syndromes
reflects genetically determined functional defects of kidney
transporters and ion channels, leading to a puzzling clinical
picture characterized by hypokalemia, sodium depletion,
activation of the renin–angiotensin–aldosterone system with
increased plasma levels of Ang II, yet normo–hypotension,
reduced peripheral resistance, and hyporesponsiveness to
pressor agents.8,9 The identification of the genetic defects of
Bartter’s/Gitelman’s syndromes clarified the pathogenesis of
these diseases and established that the hyporesponsiveness to
pressor agents and normo–hypotension are secondary to muta-
tions in cotransporters and ion channels determining Na
and K wasting, which, together with volume contraction, are
the major consequences of Bartter’s/Gitelman’s syndromes
genetic abnormalities.8,9 Bartter’s/Gitelman’s syndrome has
been considered a good human model to explore the
mechanisms responsible for maintenance/controlling vascular
tone.8,10 Bartter’s/Gitelman’s syndrome has, in fact, attracted
much attention for its persistent normo/hypotension despite
biochemical and hormonal abnormalities typical of hyper-
tension. Therefore, understanding why patients with Bart-
ter’s/Gitelman’s syndromes do not develop hypertension, in
spite of high Ang II and activation of the renin–angiotensi-
n–aldosterone system, could shed light on the cellular basis of
hypertension. In our extensive studies in Bartter’s/Gitelman’s
syndrome, we have provided important insights into the
mechanistic details of Ang II-related pathways for vascular
tone regulation.7,8,10
G PROTEINS, REGULATORS OF G-PROTEIN SIGNALING AND
NITRIC OXIDE SYSTEM
In hypertension, the Ang II-mediated signaling is known to
be activated, whereas NO production is reduced.2 In
particular, two heterotrimeric and one monomeric G-protein
systems are essentially activated by Ang II after binding of the
peptide to Ang II type 1 receptor subtype (AT1) to lead to
vascular smooth muscle contraction: the heterotrimeric Gq
and Gi protein systems,11,12 whose a subunits bind and
hydrolyze guanosine triphosphate and confer specificity in
receptor and effector interactions, and the monomeric RhoA
system.13 The a subunit of the Gq protein transduces the Ang
II signal to phospholipase Cb to generate inositol trispho-
sphate and diacylglycerol3 and activation of protein kinase C
leading to vascular smooth muscle contraction,3 whereas the
a subunit of the Gi protein transduces the Ang II signal to
adenyl cyclase leading to decreased formation of the
vasodilatory cyclic adenosine monophosphate (cAMP).12,14
The RhoA pathway modulates, through the activity of its
main effector Rho kinase (ROK), the phosphorylation state
of the regulatory chain of myosin II, mainly through
inhibition of myosin phosphatase, and contributes to
agonist-induced Ca2þ sensitization in smooth muscle
contraction.13,15 The ultimate effect is to increase smooth
muscle cell contraction.
In patients with Bartter’s/Gitelman’s syndrome, notwith-
standing the activation of the renin–angiotensin–aldosterone
system and the increased plasma levels of Ang II, we have,
instead, documented a reduced gene and protein expression
of the a subunit of Gq protein16,17 and decreased downstream
intracellular events, such as intracellular Ca2þ and inositol
trisphosphate release and protein kinase C activation.16,18,19
In addition, we recently found in Bartter’s/Gitelman’s
patients a reduced expression and response of ROK upon
Ang II challenge, which indicates downregulation of RhoA/
ROK pathway.20 The reduced ROK in Bartter’s/Gitelman’s
patients was associated with increased expression of the
endothelial subunit of NO synthase mRNA,21 alongside with
upregulation of NO system,21,22 which reflects, in humans,
the upregulation of NO system upon ROK inhibition shown
in endothelial cells and ‘in vivo’ in Dahl hypertensive rats and
contended to lead to cardiovascular protection.23,24 More-
over, patients with Bartter’s/Gitelman’s syndrome may also
present activation of Akt pathway, reported after ROK
inhibition,23 as we have shown that these patients have an
increased expression of heme-oxygenase-1,25 a known
antiapoptotic and antioxidant enzyme,26 whose expression
is induced by Akt.27
The activation of RhoA is, instead, upregulated by Rho
guanine nucleotide exchange factor (RhoGEF), which links
activation of G-protein-coupled receptors to RhoA/ROK
signaling.28–30 Overexpression of regulator of G-protein
signaling (RGS) domain containing RhoGEF has been
recently shown in SHR rats, indicating that RhoGEF may
contribute to increased activation of RhoA/Rho-kinase
pathway in hypertension.31
Signaling of Ang II by G-protein-coupled receptors is
regulated by RGS proteins, which act as guanosine tripho-
sphatase-activating proteins for Ga subunits and also
competitively inhibit Ga binding to effectors such as
phospholipase C.30,32,33 The guanosine triphosphatase-acti-
vating protein activity of RGS reduces the steady-state level of
guanosine triphosphate-bound Ga subunit, thus turning off
G protein signal.30,32,33 The role of RGS-2 in G-protein-
coupled receptor-mediated blood pressure control and as key
control element of Ang II signaling (acting as a negative
regulator of the a subunit of Gq protein) has been
investigated in an RGS-2 knockout mouse model, where
partial or complete deletion of RGS-2 causes hypertension.34
NO and cyclic guanosine monophosphate, its second
messenger, increase RGS-2 guanosine triphosphatase activity
of Gq protein by activating and binding cyclic guanosine
monophosphate-dependent protein kinase 1-a to RGS-2.35
Protein kinase 1-a phosphorylates RGS-2, dephosphorylates
myosin light chain, and induces vascular smooth muscle cell
relaxation. These findings suggest that RGS-2 is also central
for the vasorelaxing activity of NO.35 Very recently, the role of
RGS-2 acting as a negative regulator of the a subunit of Gi
protein (Gai2) has also been demonstrated in A10 vascular
smooth muscle cells36 through the attenuation of Gi-
mediated adenylyl cyclase signaling, which, with the resultant
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increased level of cAMP, may play a role in the regulation of
blood pressure by decreasing vascular resistance.36
In patients with Bartter’s/Gitelman’s syndrome, we found
an increased gene and protein expression of RGS-2,37 which
explains the downregulation of Gq protein signaling16–19 and
is consistent with the reduced peripheral resistance, vascular
hyporeactivity, and normo–hypotension, which is typical of
Bartter’s/Gitelman’s patients.
The maximally stimulated RGS-2 gene and protein
expression in Bartter’s/Gitelman’s patients compared to
healthy normotensive controls, as shown by the failure of
Ang II ‘in vitro’ to further increase RGS-2 expression,37 is of
direct relevance to the recent demonstration in A10 vascular
smooth muscle cells that RGS-2 negatively regulates Gai-
mediated signaling, suggesting that the RGS-2-mediated
attenuation of Gi-mediated adenylyl cyclase signaling may
play an important role in the regulation of blood pressure by
increasing cAMP levels and decreasing vascular resistance.36
The reduced RGS-2 gene and protein expression38 and
increased expression of Gai2
39 we have shown in patients
with essential hypertension parallel the known reduced
cAMP level present in hypertension and also support a role
of RGS-2 in the regulation of Gi-mediated signaling. In
addition, the upregulation of RGS-2 in Bartter’s/Gitelman’s
syndrome is paralleled by increased cAMP levels,40 further
supporting a role of RGS-2-mediated downregulation in
Gi-mediated signaling.
The usefulness of Bartter’s/Gitelman’s syndrome in
exploring Ang II signaling is also strengthened by the
demonstration that the gene and protein expression of the
upstream regulator of RhoA, p115RhoGEF, is reduced
compared with normotensive controls.41 Not only does this
downregulation of p115RhoGEF explain the reduced level
and response to Ang II of ROK found in Bartter’s and
Gitelman’s syndromes,20 but these data agree with those
obtained in vitro in a hypertensive rat model,31 thereby
confirming that RhoGEF level has a major impact on blood
pressure regulation.
OXIDATIVE STRESS AND THE ANGIOTENSIN II LONG-TERM
SIGNALING
The cellular effects mediated by long-term signaling of Ang II
cause cardiovascular remodeling, common to hypertension,
atherosclerosis, heart and kidney failure, that occurs
predominantly through modulation of the cell oxidative
state.1,2,42 Ang II increases oxidative stress via upregulation of
nicotinamide adenine dinucleotide/nicotinamide adenine
dinucleotide phosphate (NADH/NADPH) oxidase, the major
superoxide (O2
)-generating enzyme, with consequent O2

overproduction.43 Activation of p22phox, a 22 kDa a subunit
of cytochrome b558 included in the NADH/NADPH oxidase,
plays a key role, as it functions as an integral subunit of the
final electron transport from NADPH to heme and molecular
oxygen in generating O2
, and is stimulated by Ang II.43 This
pathway also involves the induction of established oxidative
stress-related effectors such as transforming growth factor b44
and protein kinase C, which activate oxidative stress-related
kinases such as mitogen-activated protein kinase/extracellular
signal-regulated kinase,45 ultimately leading to cardiovascular
remodeling and atherogenesis. This pathway is counter-
balanced by the activity of both NO and heme oxygenase-1
systems.2,26 These systems are involved in defense against
oxidative stress,26 and are regulated by redox-dependent
and -independent stimuli.46 For example, stimuli such as
the intracellular messenger cAMP and cyclic guanosine
monophosphate lead to vasodilation through the heme
oxygenase-1-induced production of the vasodilatory carbon
monoxide.26 The Ang II-induced upregulation of NAD(P)H
oxidase,43 and increased free radical production that results,
reduces NO bioavailability, thereby impairing NO-dependent
vasodilation and increasing vascular oxidative stress. These
effects then result in hypertension and cardiovascular
remodeling.1,2,42 The causative role of NAD(P)H activation
and oxidative stress for the induction of cardiovascular
remodeling in hypertension is further strengthened by the
reduced biochemical and molecular signs of cardiomyocyte
hypertrophy in Dahl salt-sensitive hypertensive rats upon
ROK inhibition that paralleled the reduced content of the
various subunits of NAD(P)H oxidase and oxidative stress-
related proteins such as transforming growth factor b, as well
as lectin-like ox-low-density lipoprotein receptor-1.24
Again, Bartter’s/Gitelman’s syndrome patients showed
reduced gene expression and response to Ang II of p22phox,
transforming growth factor b, and plasminogen activator
inhibitor type-1.20,25 Moreover, they had reduced low-density
lipoprotein oxidative susceptibility, increased plasma anti-
oxidant power, along with upregulation of NO system and
the downregulation of RhoA/ROK pathway.20–22,41,47 All
point toward a blunted long-term signaling pathway of Ang
II, with resultant reduced cell redox state and increased
protection toward cardiovascular remodeling. Therefore,
Bartter’s/Gitelman’s syndrome patients exhibit a spectrum
of biochemical and enzymatic responses that, while opposite
the upregulation found in hypertension, are mediated by the
very same pathways found in hypertension.10,48,49
CONCLUSIONS
Extensive studies of patients with Bartter’s/Gitelman’s
syndromes performed by our group have shown that the
Ang II signaling pathways most prominent in mediating most
of the known hemodynamic and endocrine effects of that
peptide, including vasoconstriction and cardiovascular re-
modeling, are blunted. Integrating our findings, the bio-
chemical abnormalities of Ang II signaling present in
Bartter’s/Gitelman’s syndrome produce a mirror image of
those found in hypertension. That is, whereas in hyperten-
sion, cellular pathways induced by Ang II are upregulated,
these are blunted in Bartter’s/Gitelman’s patients, thereby
making these syndromes a useful human model for the study
of not only the pathophysiological mechanisms of human
hypertension but more general physiology of vascular tone
regulation as well. It seems, in fact, that nature has provided a
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clinical model for evaluating and understanding mechanisms
involved in Ang II signaling in hypertension, and our studies
in Bartter’s/Gitelman’s syndromes have provided insight into
those mechanisms the loss/alteration of which leads to
conditions such as hypertension and vascular remodeling on
the one hand, or to conditions of vascular hyporeactivity
such as Bartter’s/Gitelman’s syndromes, on the other.
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